These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Chromatin Interactions and Regulatory Elements in Cancer: From Bench to Bedside. See YX; Wang BZ; Fullwood MJ Trends Genet; 2019 Feb; 35(2):145-158. PubMed ID: 30577989 [TBL] [Abstract][Full Text] [Related]
26. Role of proto-oncogene activation in carcinogenesis. Anderson MW; Reynolds SH; You M; Maronpot RM Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840 [TBL] [Abstract][Full Text] [Related]
27. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors. Spandidos DA Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595 [TBL] [Abstract][Full Text] [Related]
28. Enhancer Dysfunction in 3D Genome and Disease. Xia JH; Wei GH Cells; 2019 Oct; 8(10):. PubMed ID: 31635067 [TBL] [Abstract][Full Text] [Related]
29. Leveraging Tissue-Specific Enhancer-Target Gene Regulatory Networks Identifies Enhancer Somatic Mutations That Functionally Impact Lung Cancer. Hariprakash JM; Salviato E; La Mastra F; Sebestyén E; Tagliaferri I; Silva RS; Lucini F; Farina L; Cinquanta M; Rancati I; Riboni M; Minardi SP; Roz L; Gorini F; Lanzuolo C; Casola S; Ferrari F Cancer Res; 2024 Jan; 84(1):133-153. PubMed ID: 37855660 [TBL] [Abstract][Full Text] [Related]
30. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Chen H; Li C; Peng X; Zhou Z; Weinstein JN; ; Liang H Cell; 2018 Apr; 173(2):386-399.e12. PubMed ID: 29625054 [TBL] [Abstract][Full Text] [Related]
31. Eukaryotic enhancers: common features, regulation, and participation in diseases. Erokhin M; Vassetzky Y; Georgiev P; Chetverina D Cell Mol Life Sci; 2015 Jun; 72(12):2361-75. PubMed ID: 25715743 [TBL] [Abstract][Full Text] [Related]
32. Hijacked enhancer-promoter and silencer-promoter loops in cancer. Wang X; Yue F Curr Opin Genet Dev; 2024 Jun; 86():102199. PubMed ID: 38669773 [TBL] [Abstract][Full Text] [Related]
33. Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations. Taberlay PC; Achinger-Kawecka J; Lun AT; Buske FA; Sabir K; Gould CM; Zotenko E; Bert SA; Giles KA; Bauer DC; Smyth GK; Stirzaker C; O'Donoghue SI; Clark SJ Genome Res; 2016 Jun; 26(6):719-31. PubMed ID: 27053337 [TBL] [Abstract][Full Text] [Related]
34. Towards genome-wide prediction and characterization of enhancers in plants. Marand AP; Zhang T; Zhu B; Jiang J Biochim Biophys Acta Gene Regul Mech; 2017 Jan; 1860(1):131-139. PubMed ID: 27321818 [TBL] [Abstract][Full Text] [Related]
35. Molecular Basis of the Function of Transcriptional Enhancers. Ibragimov AN; Bylino OV; Shidlovskii YV Cells; 2020 Jul; 9(7):. PubMed ID: 32635644 [TBL] [Abstract][Full Text] [Related]
36. When deletions gain functions: commandeering epigenetic mechanisms. Chen J; Weiss WA Cancer Cell; 2014 Aug; 26(2):160-1. PubMed ID: 25117708 [TBL] [Abstract][Full Text] [Related]
37. Super enhancers-Functional cores under the 3D genome. Zhang J; Yue W; Zhou Y; Liao M; Chen X; Hua J Cell Prolif; 2021 Feb; 54(2):e12970. PubMed ID: 33336467 [TBL] [Abstract][Full Text] [Related]
38. Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding Influences Tumorigenic Transcriptional Programs. Nuñez-Olvera SI; Puente-Rivera J; Ramos-Payán R; Pérez-Plasencia C; Salinas-Vera YM; Aguilar-Arnal L; López-Camarillo C Cells; 2021 Dec; 11(1):. PubMed ID: 35011637 [TBL] [Abstract][Full Text] [Related]
39. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets. Bacabac M; Xu W Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907 [TBL] [Abstract][Full Text] [Related]